{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:14:49Z","timestamp":1793657689198,"version":"4.5.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Trastuzumab, as the gold standard for HER2-positive BC treatment, was the first-line HER2 targeted drug. However, some studies reported patients benefited more from lapatinib and lapatinib plus trastuzumab therapy than standard trastuzumab therapy. This study presents an update of a systematic review and meta-analysis involving comparison of lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>We determined whether trastuzumab plus lapatinib or lapatinib therapy is not inferior to trastuzumab therapy in HER2-positive breast cancer patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Relevant trials were searched in CNKI, Wanfang, VIP, Sinomed, PubMed, Embase, and Cochrane CENTRAL databases from inception until October 25, 2021. Primary outcomes were OS, DFS\/EFS, and PFS while secondary outcomes were pCR (ypT0\/is ypN0), pCR (ypT0\/is ypN0\/+), ORR, DCR, rate of BCS, RFS, cardiac toxicities, and other toxicities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirteen randomized controlled trials were included in this study. Trastuzumab combined with lapatinib therapy was found to be superior to standard trastuzumab therapy alone with regard to overall survival, disease-free survival\/event-free survival, pathologic complete response (ypT0\/is ypN0), pathologic complete response (ypT0\/is ypN0\/+), recurrence-free survival, higher incidences of diarrhea, and rash\/skin toxicity. Lapatinib therapy was established to be inferior to trastuzumab therapy in overall survival, progression-free survival, disease-free survival\/event-free survival, pathologic complete response (ypT0\/is ypN0) and pathologic complete response (ypT0\/is ypN0\/+), diarrhea, and rash\/skin toxicity and had a low incidence of left ventricular ejection fraction decline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The efficacy of trastuzumab combined with lapatinib therapy is superior to standard trastuzumab therapy alone; however, it has more non-cardiac grade III\/IV toxicities. Moreover, the efficacy of lapatinib therapy is inferior to that of standard trastuzumab therapy alone.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13643-022-02134-9","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T10:02:38Z","timestamp":1670666558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis"],"prefix":"10.1186","volume":"11","author":[{"given":"Ye","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xumei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-684X","authenticated-orcid":false,"given":"Wenyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"issue":"1","key":"2134_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7\u201333.","journal-title":"CA Cancer J Clin."},{"issue":"2","key":"2134_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2174\/1871520616666160502122724","volume":"17","author":"S Nagini","year":"2017","unstructured":"Nagini S. Breast cancer: current molecular therapeutic targets and new players. Anticancer Agents Med Chem. 2017;17(2):152\u201363.","journal-title":"Anticancer Agents Med Chem."},{"issue":"7","key":"2134_CR3","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.31557\/APJCP.2019.20.7.2015","volume":"20","author":"N Azamjah","year":"2019","unstructured":"Azamjah N, Soltan-Zadeh Y, Zayeri F. Global trend of breast cancer mortality rate: a 25-year study. Asian Pac J Cancer Prev. 2019;20(7):2015\u201320.","journal-title":"Asian Pac J Cancer Prev."},{"issue":"10","key":"2134_CR4","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/1055-9965.EPI-18-0098","volume":"27","author":"RM Pfeiffer","year":"2018","unstructured":"Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH. Proportion of U.S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev. 2018;27(10):1214\u201322.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"11","key":"2134_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.trecan.2017.09.001","volume":"3","author":"SK Yeo","year":"2017","unstructured":"Yeo SK, Guan JL. Breast cancer: multiple subtypes within a tumor? Trends Cancer. 2017;3(11):753\u201360.","journal-title":"Trends Cancer."},{"key":"2134_CR6","volume-title":"StatPearls. Treasure Island (FL)","author":"SA Albagoush","year":"2021","unstructured":"Albagoush SA, Limaiem F. HER2. 2020. In:  StatPearls. Treasure Island (FL): StatPearls Publishing; 2021."},{"issue":"1","key":"2134_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4132\/jptm.2019.11.03","volume":"54","author":"S Ahn","year":"2020","unstructured":"Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020 Jan;54(1):34\u201344.","journal-title":"J Pathol Transl Med."},{"issue":"10087","key":"2134_CR8","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415\u201329.","journal-title":"Lancet."},{"issue":"1","key":"2134_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020 Jan;17(1):33\u201348.","journal-title":"Nat Rev Clin Oncol."},{"key":"2134_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.breast.2018.03.006","volume":"39","author":"S Escriv\u00e1-de-Roman\u00ed","year":"2018","unstructured":"Escriv\u00e1-de-Roman\u00ed S, Arum\u00ed M, Bellet M, Saura C. HER2-positive breast cancer: current and new therapeutic strategies. Breast. 2018 Jun;39:80\u20138.","journal-title":"Breast."},{"issue":"2","key":"2134_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-016-0162-9","volume":"30","author":"S Maximiano","year":"2016","unstructured":"Maximiano S, Magalh\u00e3es P, Guerreiro MP, Morgado M. Trastuzumab in the treatment of breast cancer. BioDrugs. 2016;30(2):75\u201386.","journal-title":"BioDrugs."},{"issue":"4","key":"2134_CR12","first-page":"1045","volume":"10","author":"J Kreutzfeldt","year":"2020","unstructured":"Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. Am J Cancer Res. 2020;10(4):1045\u201367.","journal-title":"Am J Cancer Res."},{"issue":"4","key":"2134_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ccl.2019.07.005","volume":"37","author":"R Barish","year":"2019","unstructured":"Barish R, Gates E, Barac A. Trastuzumab-induced cardiomyopathy. Cardiol Clin. 2019;37(4):407\u201318.","journal-title":"Cardiol Clin."},{"key":"2134_CR14","unstructured":"Greenblatt K, Khaddour K. Trastuzumab. 2021 Jul 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan\u2013."},{"issue":"10075","key":"2134_CR15","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. Herceptin Adjuvant (HERA) Trial Study Team. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195\u2013205.","journal-title":"Lancet."},{"issue":"Suppl 1","key":"2134_CR16","first-page":"21","volume":"10","author":"M Luque-Cabal","year":"2016","unstructured":"Luque-Cabal M, Garc\u00eda-Teijido P, Fern\u00e1ndez-P\u00e9rez Y, S\u00e1nchez-Lorenzo L, Palacio-V\u00e1zquez I. Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it. Clin Med Insights Oncol. 2016;10(Suppl 1):21\u201330.","journal-title":"Clin Med Insights Oncol."},{"key":"2134_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-3-319-91442-8_2","volume":"211","author":"M Voigtlaender","year":"2018","unstructured":"Voigtlaender M, Schneider-Merck T, Trepel M. Lapatinib. Recent Results Cancer Res. 2018;211:19\u201344.","journal-title":"Recent Results Cancer Res."},{"issue":"1","key":"2134_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","volume":"7","author":"I Schlam","year":"2021","unstructured":"Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. NPJ Breast Cancer. 2021;7(1):56.","journal-title":"NPJ Breast Cancer."},{"issue":"1","key":"2134_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1200\/JCO.20.01894","volume":"39","author":"SRD Johnston","year":"2021","unstructured":"Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE. J Clin Oncol. 2021;39(1):79\u201389.","journal-title":"J Clin Oncol."},{"key":"2134_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ejca.2021.01.053","volume":"148","author":"A Moreno-Aspitia","year":"2021","unstructured":"Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, et al. ALTTO Steering Committee and Investigators. Updated results from the international phase III ALTTO trial (BIG 2-06\/Alliance N063D). Eur J Cancer. 2021;148:287\u201396.","journal-title":"Eur J Cancer."},{"key":"2134_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2021.05.018","volume":"153","author":"V Guarneri","year":"2021","unstructured":"Guarneri V, Dieci MV, Griguolo G, Miglietta F, Girardi F, Bisagni G, et al. Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: survival analyses of the CHER-Lob trial. Eur J Cancer. 2021;153:133\u201341.","journal-title":"Eur J Cancer."},{"issue":"1","key":"2134_CR22","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1038\/s41467-020-19494-2","volume":"11","author":"SA Hurvitz","year":"2020","unstructured":"Hurvitz SA, Caswell-Jin JL, McNamara KL, Zoeller JJ, Bean GR, Dichmann R, et al. Pathologic and molecular responses to neoadjuvant trastuzumab and\/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nat Commun. 2020;11(1):5824.","journal-title":"Nat Commun."},{"key":"2134_CR23","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ."},{"key":"2134_CR24","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JP Higgins","year":"2010","unstructured":"Higgins JP. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken, NJ, USA: John Wiley & Sons; 2010."},{"issue":"7109","key":"2134_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"10","key":"2134_CR26","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","volume":"34","author":"M Piccart-Gebhart","year":"2016","unstructured":"Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and\/or trastuzumab treatment optimization trial. J Clin Oncol. 2016;34(10):1034\u201342.","journal-title":"J Clin Oncol."},{"issue":"9","key":"2134_CR27","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1634\/theoncologist.2015-0138","volume":"20","author":"V Guarneri","year":"2015","unstructured":"Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, et al. Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer. Oncologist. 2015 Sep;20(9):1001\u201310.","journal-title":"Oncologist."},{"issue":"16","key":"2134_CR28","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1200\/JCO.2011.39.0823","volume":"30","author":"V Guarneri","year":"2012","unstructured":"Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012;30(16):1989\u201395.","journal-title":"J Clin Oncol."},{"issue":"35","key":"2134_CR29","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.20.01276","volume":"38","author":"A Fernandez-Martinez","year":"2020","unstructured":"Fernandez-Martinez A, Krop IE, Hillman DW, Polley MY, Parker JS, Huebner L, et al. Survival, pathologic response, and genomics in CALGB 40601 (alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer. J Clin Oncol. 2020;38(35):4184\u201393.","journal-title":"J Clin Oncol."},{"issue":"6","key":"2134_CR30","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1200\/JCO.2015.62.1268","volume":"34","author":"LA Carey","year":"2016","unstructured":"Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol. 2016;34(6):542\u20139.","journal-title":"J Clin Oncol."},{"key":"2134_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejca.2019.04.038","volume":"118","author":"J Huober","year":"2019","unstructured":"Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, et al. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer. 2019;118:169\u201377.","journal-title":"Eur J Cancer."},{"issue":"10","key":"2134_CR32","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","volume":"15","author":"E de Azambuja","year":"2014","unstructured":"de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15(10):1137\u201346.","journal-title":"Lancet Oncol."},{"issue":"8","key":"2134_CR33","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1093\/annonc\/mdt129","volume":"24","author":"C Criscitiello","year":"2013","unstructured":"Criscitiello C, Azim HA Jr, Agbor-tarh D, de Azambuja E, Piccart M, Baselga J, et al. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol. 2013 Aug;24(8):1980\u20135.","journal-title":"Ann Oncol."},{"issue":"9816","key":"2134_CR34","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","volume":"379","author":"J Baselga","year":"2012","unstructured":"Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633\u201340.","journal-title":"Lancet."},{"issue":"13","key":"2134_CR35","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1200\/JCO.2017.75.9175","volume":"36","author":"M Untch","year":"2018","unstructured":"Untch M, von Minckwitz G, Gerber B, Schem C, Rezai M, Fasching PA, et al. Survival analysis after neoadjuvant chemotherapy with trastuzumab or lapatinib in patients with human epidermal growth factor receptor 2-positive breast cancer in the GeparQuinto (G5) study (GBG 44). J Clin Oncol. 2018;36(13):1308\u201316.","journal-title":"J Clin Oncol."},{"issue":"2","key":"2134_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1470-2045(11)70397-7","volume":"13","author":"M Untch","year":"2012","unstructured":"Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135\u201344.","journal-title":"Lancet Oncol."},{"key":"2134_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.breast.2018.04.010","volume":"40","author":"T Takano","year":"2018","unstructured":"Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, et al. A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B\/ELTOP. Breast. 2018 Aug;40:67\u201375.","journal-title":"Breast."},{"issue":"14","key":"2134_CR38","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.2014.57.1794","volume":"33","author":"X Pivot","year":"2015","unstructured":"Pivot X, Manikhas A, \u017burawski B, Chmielowska E, Karaszewska B, Allerton R, et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015;33(14):1564\u201373.","journal-title":"J Clin Oncol."},{"issue":"14","key":"2134_CR39","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1200\/JCO.2014.56.9590","volume":"33","author":"KA Gelmon","year":"2015","unstructured":"Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol. 2015;33(14):1574\u201383.","journal-title":"J Clin Oncol."},{"issue":"2","key":"2134_CR40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdu551","volume":"26","author":"H Bonnefoi","year":"2015","unstructured":"Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-Bouvet L, Zaman K, et al. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Ann Oncol. 2015;26(2):325\u201332.","journal-title":"Ann Oncol."},{"issue":"5","key":"2134_CR41","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/bjc.2013.831","volume":"110","author":"E Alba","year":"2014","unstructured":"Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, S\u00e1nchez-Rovira P, et al. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM\/2006-14 trial. Br J Cancer. 2014;110(5):1139\u201347.","journal-title":"Br J Cancer."},{"issue":"12","key":"2134_CR42","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S1470-2045(13)70411-X","volume":"14","author":"A Robidoux","year":"2013","unstructured":"Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(12):1183\u201392.","journal-title":"Lancet Oncol."},{"issue":"6","key":"2134_CR43","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/1756-0500-6-507","volume":"5","author":"FA Holmes","year":"2013","unstructured":"Holmes FA, Espina V, Liotta LA, Nagarwala YM, Danso M, McIntyre KJ, et al. Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. BMC Res Notes. 2013;5(6):507.","journal-title":"BMC Res Notes."},{"issue":"2020","key":"2134_CR44","first-page":"5169278","volume":"16","author":"L Yu","year":"2020","unstructured":"Yu L, Fu F, Li J, Huang M, Zeng B, Lin Y, et al. Dual HER2 blockade versus a single agent in trastuzumab-containing regimens for HER2-positive early breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Oncol. 2020;16(2020):5169278.","journal-title":"J Oncol."},{"issue":"18","key":"2134_CR45","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1158\/1078-0432.CCR-15-1881","volume":"22","author":"M Clavarezza","year":"2016","unstructured":"Clavarezza M, Puntoni M, Gennari A, Paleari L, Provinciali N, D'Amico M, et al. Dual block with lapatinib and trastuzumab versus single-agent trastuzumab combined with chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials. Clin Cancer Res. 2016;22(18):4594\u2013603.","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2134_CR46","doi-asserted-by":"publisher","first-page":"e013053","DOI":"10.1136\/bmjopen-2016-013053","volume":"7","author":"ZQ Xu","year":"2017","unstructured":"Xu ZQ, Zhang Y, Li N, Liu PJ, Gao L, Gao X, et al. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(3):e013053.","journal-title":"BMJ Open."},{"issue":"12","key":"2134_CR47","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2147\/OTT.S183304","volume":"3","author":"W Ma","year":"2019","unstructured":"Ma W, Zhao F, Zhou C, Zhang Y, Zhao Y, Li N, et al. Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis. Onco Targets Ther. 2019;3(12):379\u201390.","journal-title":"Onco Targets Ther."},{"issue":"2","key":"2134_CR48","doi-asserted-by":"publisher","first-page":"100433","DOI":"10.1016\/j.esmoop.2022.100433","volume":"7","author":"V Guarneri","year":"2022","unstructured":"Guarneri V, Griguolo G, Miglietta F, Conte PF, Dieci MV, Girardi F. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials. ESMO Open. 2022;7(2):100433.","journal-title":"ESMO Open."},{"issue":"8","key":"2134_CR49","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3389\/fcell.2020.00434","volume":"3","author":"W Ma","year":"2020","unstructured":"Ma W, Wei S, Zhang B, Li W. Molecular Mechanisms of Cardiomyocyte Death in Drug-Induced Cardiotoxicity. Front Cell Dev Biol. 2020;3(8):434.","journal-title":"Front Cell Dev Biol."},{"issue":"8","key":"2134_CR50","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s00018-019-03340-w","volume":"77","author":"K Leemasawat","year":"2020","unstructured":"Leemasawat K, Phrommintikul A, Chattipakorn SC, Chattipakorn N. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients. Cell Mol Life Sci. 2020;77(8):1571\u201389.","journal-title":"Cell Mol Life Sci."},{"issue":"4","key":"2134_CR51","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00280-020-04040-0","volume":"85","author":"BJ Mayo","year":"2020","unstructured":"Mayo BJ, Secombe KR, Wignall AD, Bateman E, Thorpe D, Pietra C, et al. The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats. Cancer Chemother Pharmacol. 2020;85(4):793\u2013803.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"8","key":"2134_CR52","doi-asserted-by":"publisher","first-page":"djw037","DOI":"10.1093\/jnci\/djw037","volume":"108","author":"A Sonnenblick","year":"2016","unstructured":"Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, et al. Lapatinib-related rash and breast cancer outcome in the ALTTO phase III randomized trial. J Natl Cancer Inst. 2016;108(8):djw037.","journal-title":"J Natl Cancer Inst"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-022-02134-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-022-02134-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-022-02134-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T14:08:58Z","timestamp":1670940538000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-022-02134-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2134"],"URL":"https:\/\/doi.org\/10.1186\/s13643-022-02134-9","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,10]]},"assertion":[{"value":"24 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not need ethics because there is no private information of participants involved. The present study results will be disseminated to a peer-reviewed journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}